Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive

POST MARKETING SURVEILLANCE TO OBSERVE THE SAFETY AND EFFICACY OF DUAVIVE TAB 0.45MG/20MG

To evaluate safety and efficacy of CE/BZA in real practice in Korea

Inclusion Criteria:

1. Severe post menopausal vasomotor symptoms with uterus
2. postmenopausal osteopenia

Exclusion Criteria:

• Women with undiagnosed abnormal uterine bleeding
• Women with known, suspected, or past history of breast cancer
• Women with known or suspected estrogen-dependent neoplasia
• Women with active deep venous thrombosis, pulmonary embolism, or history of these conditions
• Women with active arterial thromboembolic disease (for example, stroke, myocardial infarction) or history of these conditions
• Women who are receiving progestin, estrogen, or estrogen-agonists/antagonists
• Women with hypersensitivity (for example, anaphylaxis, angioedema) to estrogens, bazedoxifene, or any ingredients
• Women with known hepatic impairment or disease
• Women with known protein C, protein S, or antithrombin deficiency or other known thrombophilic disorders
• Pregnant women, women who may become pregnant, and nursing mothers
• Women with hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption.